TriangleNCT00063713 · CITED IN SOURCE DOCUMENTS
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2008-02-11
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria * 18 years of age or older * Confirmed diagnosis of mantle cell lymphoma * Documented relapse or progressive disease following 1 or 2 prior lines of anti-cancer therapy. At least one of those regimens must have included an anthracycline or mitoxantrone. Relapsed or progressive disease, since last therapy must be documented by new lesions or objective evidence of the progression of existing lesions. * At least 1 measurable or evaluable site of disease * Voluntary consent Exclusion Criteria * Previous treatment with VELCADE * Any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug * Radiation therapy within 3 weeks before the first dose of study drug * Major surgery with 2 weeks before the first dose of study drug * Rituximab, Campath, or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug * Radioimmunotherapy or other toxin immunoconjugates such as Zevalin or Bexxar within 10 weeks before the first dose of study drug * History of allergic reactions to boron or mannitol compounds * Diagnosed or treated for another malignancy other than mantle cell lymphoma with 5 years before the first dose of study drug * Active systemic infection requiring treatment * Women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are post-menopausal or surgically sterile) * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * Concurrent treatment with another investigational drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- name
- VELCADE TM (bortezomib) for Injection
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 152
Registered outcome plans (not posted results)
Full study description
- brief Summary
- The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
- detailed Description
- VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-1024d0d7eccbe16f5598
- requested nct id
- NCT00063713
- primary nct id
- NCT00063713
- source kind
- fda_spl_label
- source record id
- 2cc294fe-75e3-4ed9-8259-c6e5bc5e8286
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- df609b3d01943b41e9be220dd3db43ff733ee50068caa70492e6a7149287274b
- payload
- application numbers
- NDA215331
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-1024d0d7eccbe16f5598
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00063713
- occurrences
- context exact
- or Therapy The safety and efficacy of bortezomib in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study (NCT00063713) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and
- end
- 13384
- exact text
- NCT00063713
- start
- 13373
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/66/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 2cc294fe-75e3-4ed9-8259-c6e5bc5e8286
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- b137d6531114f1f5858624de253bb2dbbdc8d0c050f852c0f579236527e2c4dc
- spl effective time
- 20210922
- spl set id
- c40e6a28-d577-43d4-bca6-bef28da1d580
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-33b0e2dba25c85a79da5
- requested nct id
- NCT00063713
- primary nct id
- NCT00063713
- source kind
- fda_spl_label
- source record id
- e7c31651-e301-43f9-bc81-e0fd5dcb828c
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 751170373aa73774b18f2ec60f875a0bf42bf4a679b3ee48cff53565fe0e5464
- payload
- application numbers
- NDA209191
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-33b0e2dba25c85a79da5
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00063713
- occurrences
- context exact
- or Therapy The safety and efficacy of bortezomib in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study (NCT00063713) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and
- end
- 23112
- exact text
- NCT00063713
- start
- 23101
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/70/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- e7c31651-e301-43f9-bc81-e0fd5dcb828c
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 7027e3423ba96cab46e4309d88f4f0a790e5b56a6b8c59003ca7827474a89b28
- spl effective time
- 20230227
- spl set id
- 9fdf6169-699f-40eb-bda1-760253062b3c
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-7dd9d86af696fd52a0bb
- requested nct id
- NCT00063713
- primary nct id
- NCT00063713
- source kind
- fda_spl_label
- source record id
- 6fb2ce70-c98f-4e46-9b0f-6aec0530f61d
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 4bd314d16f95b192b6c0368645a94f72c3b81de7d628109175c6a5d0a09f35ae
- payload
- application numbers
- NDA212782
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-7dd9d86af696fd52a0bb
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00063713
- occurrences
- context exact
- or Therapy The safety and efficacy of bortezomib in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study (NCT00063713) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and
- end
- 23156
- exact text
- NCT00063713
- start
- 23145
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/45/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 6fb2ce70-c98f-4e46-9b0f-6aec0530f61d
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 8d45b20f5b82fd297b3557d8d2a3214b9206afb21de98c0176f3a11853e231e8
- spl effective time
- 20250705
- spl set id
- b92628dd-fa09-4c3a-b6a3-66426025807c
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-db8913e622d740a21094
- requested nct id
- NCT00063713
- primary nct id
- NCT00063713
- source kind
- fda_spl_label
- source record id
- 3ec85e73-696a-4a2e-aa24-656c6341b23b
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- c2951c3a15efd390052ac0875bbd98d93ade483bc45da6013fe430b277e92182
- payload
- application numbers
- NDA021602
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-db8913e622d740a21094
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00063713
- occurrences
- context exact
- rior Therapy The safety and efficacy of VELCADE in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study ( NCT00063713 ) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, an
- end
- 22911
- exact text
- NCT00063713
- start
- 22900
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/36/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 3ec85e73-696a-4a2e-aa24-656c6341b23b
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 76ced5c4383a701aa933518ad6f08bc09dfe4ed8333fbbb4f60f08431edb55f4
- spl effective time
- 20250828
- spl set id
- 1521d321-e724-4ffc-adad-34bf4f44fac7
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-f6ddaf09d4b2fa55a850
- requested nct id
- NCT00063713
- primary nct id
- NCT00063713
- source kind
- fda_spl_label
- source record id
- 71ebcbb5-31e2-4394-8a38-d833fd3c733a
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 36d7b221107b144d335893036feb9116b399cbb80e13acb769fe7ebf2f5ba5f0
- payload
- application numbers
- NDA212782
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-f6ddaf09d4b2fa55a850
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00063713
- occurrences
- context exact
- or Therapy The safety and efficacy of bortezomib in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study (NCT00063713) of 155 patients with progressive disease who had received at least one prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and
- end
- 23107
- exact text
- NCT00063713
- start
- 23096
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/49/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 71ebcbb5-31e2-4394-8a38-d833fd3c733a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 9769bacc918909c466e8f16df86bac5ef1b9ed0ca04fc11622a8845589c24249
- spl effective time
- 20240830
- spl set id
- 61539d49-dc21-4576-8813-4bc8abf3868c
Preserved source evidence · Not medical advice